Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.

Cheung LH, Zhao Y, Alvarez-Cienfuegos A, Mohamedali KA, Cao YJ, Hittelman WN, Rosenblum MG.

J Exp Clin Cancer Res. 2019 Jul 30;38(1):332. doi: 10.1186/s13046-019-1333-6.

2.

Light-enhanced VEGF121/rGel: A tumor targeted modality with vascular and immune-mediated efficacy.

Weyergang A, Fremstedal AS, Skarpen E, Peng Q, Mohamedali KA, Eng MS, Cheung LH, Rosenblum MG, Waltenberger J, Berg K.

J Control Release. 2018 Oct 28;288:161-172. doi: 10.1016/j.jconrel.2018.09.005. Epub 2018 Sep 11.

PMID:
30217739
3.

Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.

Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK.

Photochem Photobiol Sci. 2018 May 16;17(5):539-551. doi: 10.1039/C7PP00358G.

PMID:
29565434
4.

Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein.

Mohamedali KA, Rosenblum MG.

Biomedicines. 2017 Jul 17;5(3). pii: E42. doi: 10.3390/biomedicines5030042. Review.

5.

Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

Pincus SH, Song K, Maresh GA, Frank A, Worthylake D, Chung HK, Polacino P, Hamer DH, Coyne CP, Rosenblum MG, Marks JW, Chen G, Weiss D, Ghetie V, Vitetta ES, Robinson JE, Hu SL.

J Virol. 2017 Jan 18;91(3). pii: e01360-16. doi: 10.1128/JVI.01360-16. Print 2017 Feb 1.

6.

Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.

Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA.

Mol Cell. 2016 Feb 18;61(4):640. doi: 10.1016/j.molcel.2016.02.006. Epub 2016 Feb 18. No abstract available.

7.

Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.

Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA.

Mol Cell. 2016 Feb 18;61(4):520-534. doi: 10.1016/j.molcel.2016.01.015. Epub 2016 Feb 4. Erratum in: Mol Cell. 2016 Feb 18;61(4):640.

8.

The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Perez JG, Tran NL, Rosenblum MG, Schneider CS, Connolly NP, Kim AJ, Woodworth GF, Winkles JA.

Oncogene. 2016 Apr 28;35(17):2145-55. doi: 10.1038/onc.2015.310. Epub 2015 Aug 24. Review.

9.

Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.

Bull-Hansen B, Berstad MB, Berg K, Cao Y, Skarpen E, Fremstedal AS, Rosenblum MG, Peng Q, Weyergang A.

Oncotarget. 2015 May 20;6(14):12436-51.

10.

Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.

Berstad MB, Cheung LH, Berg K, Peng Q, Fremstedal AS, Patzke S, Rosenblum MG, Weyergang A.

Oncogene. 2015 Oct 29;34(44):5582-92. doi: 10.1038/onc.2015.15. Epub 2015 Feb 16.

PMID:
25684137
11.

Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.

Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG.

Mol Cancer Ther. 2014 Nov;13(11):2688-705. doi: 10.1158/1535-7163.MCT-14-0346. Epub 2014 Sep 19.

12.

Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.

Bull-Hansen B, Cao Y, Berg K, Skarpen E, Rosenblum MG, Weyergang A.

J Control Release. 2014 May 28;182:58-66. doi: 10.1016/j.jconrel.2014.03.014. Epub 2014 Mar 15.

PMID:
24637464
13.

Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.

Weyergang A, Cheung LH, Rosenblum MG, Mohamedali KA, Peng Q, Waltenberger J, Berg K.

J Control Release. 2014 Apr 28;180:1-9. doi: 10.1016/j.jconrel.2014.02.003. Epub 2014 Feb 13.

PMID:
24531010
14.

The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.

Mohamedali KA, Cao Y, Cheung LH, Hittelman WN, Rosenblum MG.

Mol Cancer Ther. 2013 Oct;12(10):2055-66. doi: 10.1158/1535-7163.MCT-13-0165. Epub 2013 Jul 15.

15.

Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.

Zhou H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA, Rosenblum MG.

Cancer Res. 2013 Jul 15;73(14):4439-50. doi: 10.1158/0008-5472.CAN-13-0187. Epub 2013 May 30.

16.

Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.

Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG.

Mol Cancer Ther. 2013 Jun;12(6):979-91. doi: 10.1158/1535-7163.MCT-13-0002. Epub 2013 Mar 14.

17.

Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.

Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG.

Oncogene. 2014 Jan 23;33(4):429-39. doi: 10.1038/onc.2012.612. Epub 2013 Feb 4.

18.

The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.

Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG.

J Invest Dermatol. 2013 Apr;133(4):1052-62. doi: 10.1038/jid.2012.402. Epub 2012 Nov 29.

19.

Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGel.

Mohamedali KA, Niu G, Luster TA, Thorpe PE, Gao H, Chen X, Rosenblum MG.

Biochem Pharmacol. 2012 Dec 1;84(11):1534-40. doi: 10.1016/j.bcp.2012.09.017. Epub 2012 Sep 26.

20.

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.

Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE.

Haematologica. 2013 Feb;98(2):217-21. doi: 10.3324/haematol.2012.071092. Epub 2012 Aug 8.

21.

The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.

Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG.

Biochem Pharmacol. 2012 Aug 15;84(4):451-8. doi: 10.1016/j.bcp.2012.05.019. Epub 2012 Jun 9.

PMID:
22687624
22.

Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles.

Zhang F, Huang X, Zhu L, Guo N, Niu G, Swierczewska M, Lee S, Xu H, Wang AY, Mohamedali KA, Rosenblum MG, Lu G, Chen X.

Biomaterials. 2012 Jul;33(21):5414-22. doi: 10.1016/j.biomaterials.2012.04.032. Epub 2012 May 3.

23.

Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.

Lyu MA, Cheung LH, Hittelman WN, Liu Y, Marks JW, Cho MJ, Rosenblum MG.

Cancer Lett. 2012 Sep 28;322(2):159-68. doi: 10.1016/j.canlet.2012.02.029. Epub 2012 Mar 1.

PMID:
22388102
24.

Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.

Parameswaran R, Yu M, Lyu MA, Lim M, Rosenblum MG, Groffen J, Heisterkamp N.

Leukemia. 2012 Aug;26(8):1786-96. doi: 10.1038/leu.2012.54. Epub 2012 Feb 29.

25.

Cell-targeting fusion constructs containing recombinant gelonin.

Lyu MA, Cao YJ, Mohamedali KA, Rosenblum MG.

Methods Enzymol. 2012;502:167-214. doi: 10.1016/B978-0-12-416039-2.00008-2. Review.

PMID:
22208986
26.

Cell Internalization Studies of Gadofullerene-(ZME-018) Immunoconjugates into A375m Melanoma Cells.

Berger CS, Marks JW, Bolskar RD, Rosenblum MG, Wilson LJ.

Transl Oncol. 2011 Dec;4(6):350-4. Epub 2011 Dec 1.

27.

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG.

Mol Cancer Ther. 2012 Jan;11(1):143-53. doi: 10.1158/1535-7163.MCT-11-0519. Epub 2011 Nov 16.

28.

Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.

Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG.

BMC Cancer. 2011 Aug 17;11:358. doi: 10.1186/1471-2407-11-358.

29.

Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.

Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, Winkles JA.

Mol Cancer Ther. 2011 Jul;10(7):1276-88. doi: 10.1158/1535-7163.MCT-11-0161. Epub 2011 May 17.

30.

Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.

Cho EJ, Yang J, Mohamedali KA, Lim EK, Kim EJ, Farhangfar CJ, Suh JS, Haam S, Rosenblum MG, Huh YM.

Invest Radiol. 2011 Jul;46(7):441-9. doi: 10.1097/RLI.0b013e3182174fad.

PMID:
21512397
31.

Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM.

Clin Cancer Res. 2011 Apr 15;17(8):2328-38. doi: 10.1158/1078-0432.CCR-10-2943. Epub 2011 Feb 22.

32.

Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin.

Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH, Rosenblum MG, Howell SB.

Cancer Chemother Pharmacol. 2011 Oct;68(4):979-90. doi: 10.1007/s00280-011-1573-4. Epub 2011 Feb 16.

33.

Multiplexed PET probes for imaging breast cancer early response to VEGF₁₂₁/rGel treatment.

Yang M, Gao H, Sun X, Yan Y, Quan Q, Zhang W, Mohamedali KA, Rosenblum MG, Niu G, Chen X.

Mol Pharm. 2011 Apr 4;8(2):621-8. doi: 10.1021/mp100446t. Epub 2011 Feb 15.

34.

Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.

Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD.

J Biol Chem. 2011 Feb 11;286(6):4165-72. doi: 10.1074/jbc.M110.186973. Epub 2010 Dec 7.

35.

Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Zhou H, Liu Y, Cheung LH, Kim S, Zhang W, Mohamedali KA, Anand P, Hittelman WN, Aggarwal BB, Rosenblum MG.

Neoplasia. 2010 Oct;12(10):766-77.

36.

Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.

Wen X, Lyu MA, Zhang R, Lu W, Huang Q, Liang D, Rosenblum MG, Li C.

Mol Imaging Biol. 2011 Aug;13(4):721-9. doi: 10.1007/s11307-010-0391-0.

37.

The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.

Lyu MA, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Rosenblum MG.

Biochem Pharmacol. 2010 Nov 1;80(9):1335-42. doi: 10.1016/j.bcp.2010.07.017. Epub 2010 Jul 21.

PMID:
20654581
38.

The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.

Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG.

Neoplasia. 2010 May;12(5):366-75.

39.

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.

Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG.

Cancer Res. 2009 Dec 1;69(23):8987-95. doi: 10.1158/0008-5472.CAN-09-2693. Epub 2009 Nov 24.

40.

Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.

Selbo PK, Rosenblum MG, Cheung LH, Zhang W, Berg K.

PLoS One. 2009 Aug 19;4(8):e6691. doi: 10.1371/journal.pone.0006691.

41.
42.

Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.

Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB.

Mol Cancer Ther. 2009 Jul;8(7):1906-15. doi: 10.1158/1535-7163.MCT-09-0106. Epub 2009 Jun 30.

43.

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.

Martínez-Torrecuadrada JL, Cheung LH, López-Serra P, Barderas R, Cañamero M, Ferreiro S, Rosenblum MG, Casal JI.

Mol Cancer Ther. 2008 Apr;7(4):862-73. doi: 10.1158/1535-7163.MCT-07-0394.

44.

Imaging of VEGF receptor in a rat myocardial infarction model using PET.

Rodriguez-Porcel M, Cai W, Gheysens O, Willmann JK, Chen K, Wang H, Chen IY, He L, Wu JC, Li ZB, Mohamedali KA, Kim S, Rosenblum MG, Chen X, Gambhir SS.

J Nucl Med. 2008 Apr;49(4):667-73. doi: 10.2967/jnumed.107.040576.

45.

Detecting and treating cancer with nanotechnology.

Hartman KB, Wilson LJ, Rosenblum MG.

Mol Diagn Ther. 2008;12(1):1-14. Review.

PMID:
18288878
46.
47.

Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli.

Kim S, Cheung LH, Zhang W, Rosenblum MG.

Appl Microbiol Biotechnol. 2007 Nov;77(1):99-106. Epub 2007 Aug 17.

PMID:
17703297
48.

Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.

Hsu AR, Cai W, Veeravagu A, Mohamedali KA, Chen K, Kim S, Vogel H, Hou LC, Tse V, Rosenblum MG, Chen X.

J Nucl Med. 2007 Mar;48(3):445-54.

49.

The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.

Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG.

Mol Cancer Ther. 2007 Feb;6(2):460-70. Epub 2007 Jan 31.

50.

Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli.

Kim S, Mohamedali KA, Cheung LH, Rosenblum MG.

J Biotechnol. 2007 Feb 20;128(3):638-47. Epub 2006 Dec 12.

PMID:
17218033

Supplemental Content

Loading ...
Support Center